Follow The Filings

ALNY Alnylam Pharmaceuticals

Health Care, filed as ALNYLAM PHARMACEUTICALS INC (COM), Equity As of 2026 Q2 among managers we track Quote on Google Finance, opens in a new tab

  • 2 Owners
  • Max 0.3%
  • $589M
  • 1 add 1 reduce

In 2026 Q2 Dodge & Cox added to Alnylam Pharmaceuticals, while Murray Stahl trimmed.

Who owns this now

Largest portfolio weights among holders, up to 0.3% (Dodge & Cox). Not free-float ownership.

  1. Dodge & Cox Add 0.31%
  2. Murray Stahl Reduce 0.01%

Who owns ALNY

Sorted by value, long equity only, as of 2026 Q2.

History
Dodge & Cox 0.31% Add +1.4% 1,955,393 $589M History
Murray Stahl, Horizon Kinetics Asset Management 0.01% Reduce −4.6% 2,168 $653K History

2 current, options excluded

Weight bar: held both quarters added sold at this quarter’s reported price

Insider trades

Open-market buys and sales by ALNY's executives, directors and 10% owners in the last 12 months, from their Form 4s

All ALNY insider trades
  • None no insider bought on the open market
  • None no sales outside a trading plan
  • $24.1M sold by 5 insiders under 10b5-1 plans
  1. David E I Pyott Director
    Planned sale
    $1.1M 3,830 shares at $299.18 71% of stake
    Traded Jun 1 Filed Jun 3
    ↗
  2. Melissa McLaughlin Chief Human Resources Officer
    Planned sale
    $755K 2,286 shares at $330.42 20% of stake
    Traded Apr 6 Filed Apr 7
    ↗
  3. Pushkal Garg EVP Chief R&D
    Planned sale
    $779K 2,404 shares at $323.96 11% of stake
    Traded Mar 5 Filed Mar 6
    ↗
  4. Kevin Joseph Fitzgerald CSO & EVP, Head of Research
    Planned sale
    $213K 658 shares at $323.98 3.1% of stake
    Traded Mar 5 Filed Mar 6
    ↗
  5. Pushkal Garg EVP Chief R&D
    Planned sale
    $568K 1,775 shares at $319.74 7% of stake
    Traded Mar 3 Filed Mar 4
    ↗
  6. Kevin Joseph Fitzgerald CSO & EVP, Head of Research
    Planned sale
    $528K 1,652 shares at $319.73 7% of stake
    Traded Mar 3 Filed Mar 4
    ↗
  7. Pushkal Garg EVP Chief R&D
    Planned sale
    $1.5M 4,627 shares at $331.34 17% of stake
    Traded Feb 27 Filed Mar 2
    ↗
  8. Kevin Joseph Fitzgerald CSO & EVP, Head of Research
    Planned sale
    $678K 2,041 shares at $331.96 8.8% of stake
    Traded Feb 17 Filed Feb 17
    ↗
  9. Kevin Joseph Fitzgerald CSO & EVP, Head of Research
    Planned sale
    $848K 2,290 shares at $370.33 9.7% of stake
    Traded Jan 13 Filed Jan 14
    ↗
  10. Kevin Joseph Fitzgerald CSO & EVP, Head of Research
    Planned sale
    $5.5M 12,128 shares at $452.18 36% of stake
    Traded Nov 17, 2025 Filed Nov 19, 2025
    ↗
  11. Yvonne Greenstreet CEO
    Planned sale
    $11.6M 25,650 shares at $452.75 28% of stake
    Traded Nov 12–13 Filed Nov 14, 2025
    ↗

Also filed in the last 12 months, not counted as buying or selling: 210 sales to cover taxes, 27 stock grants, 14 option exercises, and 1 share withholding for taxes.

Congress

3 members of Congress traded ALNY in the last three years: 1 buy and 4 sales. 3 members listed it in 2025 annual reports.

All Congress trades
  1. Cory A. Booker D-NJSpouse Sell $1K–$15K Aug 11 filed Sep 9
  2. Jefferson Shreve R-IN-6 Sell $15K–$50K May 12, 2025 filed Jun 22, 2025
  3. Josh Gottheimer D-NJ-5Joint Sell $1K–$15K Jan 29, 2024 filed Feb 15, 2024
  4. Josh Gottheimer D-NJ-5Joint Buy $1K–$15K Jan 11, 2024 filed Feb 15, 2024
  5. Josh Gottheimer D-NJ-5Joint Sell $1K–$15K Dec 11, 2023 filed Jan 7, 2024

SEC filings

Recent issuer filings from EDGAR, 14 shown.

Filed Form Detail Links
10-Q Filing Doc
8-K 2.02,9.01 Filing Doc
8-K 2.02,9.01 Filing Doc
10-Q Filing Doc
8-K 5.02,5.07 Filing Doc
SCHEDULE 13G/A — Filing Doc
SCHEDULE 13G/A — Filing Doc
SCHEDULE 13G/A — Filing Doc
8-K 2.02,9.01 Filing Doc
10-Q Filing Doc
SCHEDULE 13G — Filing Doc
DEF 14A Filing Doc
DEFA14A Filing Doc
SCHEDULE 13G/A — Filing Doc

Source: SEC EDGAR submissions, updated 1 day ago. All on EDGAR

Financials

US-GAAP annual figures by fiscal year, as tagged in Form 10-K. Each value links to its SEC filing.

Income statement

Metric FY2023 FY2024 FY2025
Revenue $1.83B $2.25B $3.71B
Gross profit * $1.56B $1.94B $3.04B
Gross margin * 85.3% 86.4% 81.8%
Net income -$440.24M -$278.16M $313.75M
Net margin * -24.1% -12.4% 8.4%

Balance sheet

Metric FY2023 FY2024 FY2025
Total current assets $2.98B $3.3B $4.05B
Total non-current assets * $847.18M $944.7M $915.67M
Total assets $3.83B $4.24B $4.97B
Total current liabilities $0.968B $1.19B $1.47B
Total non-current liabilities * $3.08B $2.99B $2.71B
Total equity -$220.64M $67.09M $789.18M

Cash flow

Metric FY2023 FY2024 FY2025
Cash from operations $104.16M -$8.31M $524.08M
Cash from investing -$336.35M -$116.84M $436.33M
Cash from financing $172.13M $294.16M -$305.19M
Net change in cash -$53.67M $153.77M $690.16M

Source: SEC companyfacts (US-GAAP 10-K). A * marks a computed figure, not a single XBRL tag. Fiscal years are as the issuer labels them. Follow The Filings does not adjust or audit these figures.

Ownership over time

13Fs that reported it each quarter. Click a bar for that quarter’s holders.